Title: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study
Abstract: HepatologyVolume 27, Issue 2 p. 311-316 Original ArticleFree Access Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study Annika Bergquist M.D., Corresponding Author Annika Bergquist M.D. Department of Gastroenterology and Hepatology, Huddinge University Hospital, Karolinska Institute, SwedenDepartment of Gastroenterology and Hepatology, Karolinska Institute, K63, Huddinge University Hospital, S-141 86 Huddinge, Sweden. Fax: 46-8-585-823-35===Search for more papers by this authorHans Glaumann, Hans Glaumann Department of Pathology, Huddinge University Hospital, Karolinska Institute, SwedenSearch for more papers by this authorBo Persson, Bo Persson Department of Radiology, Huddinge University Hospital, Karolinska Institute, SwedenSearch for more papers by this authorUlrika Broomé, Ulrika Broomé Department of Gastroenterology and Hepatology, Huddinge University Hospital, Karolinska Institute, SwedenSearch for more papers by this author Annika Bergquist M.D., Corresponding Author Annika Bergquist M.D. Department of Gastroenterology and Hepatology, Huddinge University Hospital, Karolinska Institute, SwedenDepartment of Gastroenterology and Hepatology, Karolinska Institute, K63, Huddinge University Hospital, S-141 86 Huddinge, Sweden. Fax: 46-8-585-823-35===Search for more papers by this authorHans Glaumann, Hans Glaumann Department of Pathology, Huddinge University Hospital, Karolinska Institute, SwedenSearch for more papers by this authorBo Persson, Bo Persson Department of Radiology, Huddinge University Hospital, Karolinska Institute, SwedenSearch for more papers by this authorUlrika Broomé, Ulrika Broomé Department of Gastroenterology and Hepatology, Huddinge University Hospital, Karolinska Institute, SwedenSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1002/hep.510270201Citations: 231AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract The reason why 10% to 20% of all patients with primary sclerosing cholangitis (PSC) develop cholangiocarcinoma (CC) remains unknown. The aim of this study was to compare the clinical and biochemical presentation in PSC patients with and without hepatobiliary malignancy and to look for risk factors for developing hepatobiliary carcinoma in PSC. All PSC patients (n = 20) with hepatobiliary carcinoma treated at Huddinge Hospital between 1984 and 1995 were age- and sex-matched to 20 PSC patients with end-stage disease without carcinoma. Clinical and biochemical data from four different occasions (time of onset of PSC, 12 and 6 months before and at the time of cancer diagnosis or liver transplantation [Ltx]) were registered. Seventeen patients had CC, 2 had hepatocellular carcinoma (HCC), and 1 had gallbladder carcinoma (GBC). Eighteen of the cancer patients and 19 controls had inflammatory bowel disease (IBD). The number of patients who smoked or were former smokers was significantly higher in the cancer group (P < .0004). The duration of IBD and PSC, extra- and intrahepatic distribution of PSC, surgical and medical treatments did not differ between the two groups. Abdominal pain was the only symptom that was more frequent among cancer patients at the time of cancer diagnosis/Ltx compared with controls. Evaluation of biochemical data did not indicate a more rapid deterioration among cancer patients. The mean value of the tumor marker, CA 19-9, in the cancer group was 700 kU/L; in the control group, it was 46 kU/L (P < .05), although data were only available in 10 cancer patients and 7 controls. Bile duct dysplasia was found in over 60% of patients with PSC and CC in nontumorous liver tissue apart from the tumor. Clinical and biochemical presentation of PSC patients with and without hepatobiliary carcinoma did not differ during the year before cancer diagnosis/Ltx. Smoking seems to be a risk factor for developing hepatobiliary carcinoma in patients with PSC. REFERENCES 1 Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jenssen E, Kollmannskog F. Risk factors in primary sclerosing cholangitis. J Hepatol 1994; 21: 1061– 1066.MEDLINE 2 Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430– 436.MEDLINE 3 Knechtle SJ, D'Alessandro, Harms BA, Pirsch JD, Belzer FO, Kalayoglu M. Relationships between sclerosing cholangitis, inflammatory bowel disease and cancer in patients undergoing liver transplantation. Surgery 1995; 118: 615– 620.MEDLINE 4 Broomé U, Lindberg G, Löfberg R. Primary sclerosing cholangitis in ulcerative colitis—a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992; 102: 1877– 1880.MEDLINE 5 Ekbom A, Helmick C, Zack M, Adami H-O. Ulcerative colitis and colorectal cancer. N Engl J Med 1990; 323: 1228– 1233.MEDLINE 6 Wee A, Ludwig J, Coffey RJ, La Russo NF, Wiesner RH. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol 1985; 16: 719– 725.MEDLINE 7 Mir-Madjelassi SH, Farmer RG, Sivak MV. Bile duct carcinoma in patients with ulcerative colitis. Dig Dis Sci 1987; 32: 145– 154.MEDLINE 8 Akwari OE, Van Heerden JA, Foulk WT, Baggenstoss AH. Cancer of the bile ducts associated with ulcerative colitis. Ann Surg 1975; 181: 303– 309.MEDLINE 9 Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404– 1408.MEDLINE 10 Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson Å. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610– 615.MEDLINE 11 Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213: 21– 25.MEDLINE 12 Ramage JK. Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865– 869.MEDLINE 13 Miros M, Kerlin P, Walker N, Harper J, Lynch S, Strong R. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut 1991; 32: 1369– 1373.MEDLINE 14 Martins E, Fleming KA, Garrido MC, Hine KR, Chapman R. Superficial thrombophlebitis, dysplasia, and cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1994; 107: 537– 542.MEDLINE 15 Wiesner RH, La Russo NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 74: 200– 206. 16 Chapman RWG, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer RJ, Sherlock S, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology. Gut 1980; 21: 870– 877.MEDLINE 17 Evans JG, Acheson ED. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area. Gut 1965; 6: 311– 324.MEDLINE 18 Farmer RG, Mawic WA, Turnbull RB. Clinical patterns in Crohn's disease: a statistical study of 6155 cases. Gastroenterology 1975; 68: 627– 635.MEDLINE 19 Craig DA, MacCarty RL, Wiesner RH, Grambsch PM, LaRusso NF. Primary sclerosing cholangitis: value of cholangiography in determining the prognosis. AJR 1991; 157: 959– 964. 20 Ludwig J, Barham SS, La Russo NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1: 632– 640.MEDLINE 21 Yo MC, Mack T, Hanisch R, Peters RL, Hendersson BE, Pike MC. Hepatitis, alchohol consumption, cigarette smoking, and hepatocellular carcinoma in Los Angeles. Cancer Res 1983; 43: 6077– 6079.MEDLINE 22 Yen S, Hseih C, MacMahon B. Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral conceptive use. Cancer 1987; 59: 2112– 2116.MEDLINE 23 Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton J. Primary sclerosing cholangitis is associated with nonsmoking: a case control study. Gastroenterology 1996; 110: 1496– 1502.MEDLINE 24 Van Erpecum KJ, Smits SJHM, Van de Meeberg PC, Linn FHH, Wolfhagen FHJ, vanBerge-Henegouwen GP, Algra A. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996; 110: 1503– 1506.MEDLINE 25 Nashan B, Schlitt HJ, Tusch G, Oldhafer KJ, Ringe B, Wagner S, Pichlmayr R. Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology 1996; 23: 1105– 1111.MEDLINE 26 Lundqvist K, Broomé U. Differences in colonic activity between patients with ulcerative colitis with and without concomitant primary sclerosing cholangitis. Dis Colon Rectum 1997; 40: 451– 456.MEDLINE 27 Ismail T, Angrisani L, Hübscher S, McMaster P. Hepatocellular carcinoma complicating primary sclerosing cholangitis. Br J Surg 1991; 78: 360– 361.MEDLINE 28 Ludwig J, Wahlström HE, Batts KP, Wiesner RH. Papillary bile duct dysplasia in primary sclerosing cholangitis. Gastroenterology 1992; 102: 2134– 2138.MEDLINE Citing Literature Volume27, Issue2February 1998Pages 311-316 ReferencesRelatedInformation